Progress in controlling emesis with cancer chemotherapy.
Marked progress in supportive care in cancer, and in control of chemotherapy-induced emesis in particular, has been accomplished over the past several years. Several effective antiemetic agents and regimens have been tested and are widely available. Emesis due to chemotherapy can now be completely controlled in the majority of patients. Progress in both clinical trials and in neuropharmacology has resulted in a new class of agents, the serotonin antagonists. These agents have an excellent therapeutic index and are well suited for a variety of clinical settings. Problems remain especially in the control of delayed emesis, in patients given several days of chemotherapy, and in radiation-induced emesis. Achieving the best antiemetic control, and at the same time having cost-effective therapy, is an ongoing challenge.
Gralla
R J
RJ
Ochsner Cancer Institute, New Orleans, LA 70121.
Clark
R A
RA
D000932:Antiemetics / Q000145:classification / Q000191:economics / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D016527:Drug Costs; D004359:Drug Therapy, Combination; D005544:Forecasting; D017048:Health Care Costs; D006801:Humans; D012106:Research; D012702:Serotonin Antagonists / Q000145:classification / Q000191:economics / Q000627:therapeutic use*; D014839:Vomiting / Q000139:chemically induced* / Q000188:drug therapy* / Q000191:economics
D000932:Antiemetics; D000970:Antineoplastic Agents; D012702:Serotonin Antagonists